Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279617 · ClinicalTrials.gov registry record · Phase 3
Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks
A Phase 3 study of Panic Disorder, sponsored by Lindner Center of HOPE.
- Completed
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00279617: Completed Phase 3 study of Panic Disorder, sponsored by Lindner Center of HOPE.
NCT00279617 is a Phase 3 study of Panic Disorder that has completed, run by Lindner Center of HOPE. The registered enrollment target is 15 participants, below the 222-participant average among 25 other Panic Disorder trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00279617, a Phase 3 study of Panic Disorder, has completed, sponsored by Lindner Center of HOPE.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this research study is to determine whether the drug Levetiracetam (Keppra™) is effective in the prevention of panic attacks. The drug Levetiracetam (Keppra™) has been approved for the treatment of seizures by the U.S. Federal Food and Drug Administration (FDA) and is available by prescription. Levetiracetam has not been approved by the FDA for the treatment of panic disorder.
Conditions Studied
Interventions
- DRUG levetiracetam
Study Locations (1)
Ohio
- University of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
What the finished NCT00279617 record still lists
NCT00279617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 222-participant average among 25 other Panic Disorder trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Panic Disorder appearing as the primary indexed condition, and to 1 intervention - of which levetiracetam is the first listed.
NCT00279617 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00279617 about?
NCT00279617 is a clinical study titled "Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks". The main purpose of this research study is to determine whether the drug Levetiracetam (Keppra™) is effective in the prevention of panic attacks. The drug Levetiracetam (Keppra™) has been approved for the treatment of seizures by the U.S. Federal Food and Drug Administration (FDA) and is available b...
What is the current status of trial NCT00279617?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2006-01. Estimated completion is 2009-03.
What conditions does trial NCT00279617 study?
This clinical trial studies the following conditions: Panic Disorder.
What interventions are being tested in trial NCT00279617?
The interventions under investigation include: levetiracetam (DRUG).
Who is sponsoring clinical trial NCT00279617?
This trial is sponsored by Lindner Center of HOPE, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00279617 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Panic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00279617's enrollment target sits among peer trials
15 26th of 25 the lowest of 25 other Panic Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Panic Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Telephone-Based Care Management Program for Individuals With Anxiety Disorders
COMPLETED · Phase 3
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
-
CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy
RECRUITING · NA
-
Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method
RECRUITING · NA
-
Comparative Effectiveness of Internet-based Versus Parent-Coached Cognitive-Behavioral Therapy For Children and Adolescents With Anxiety and OCD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia